Total Payments
$1.7M
2024 Payments
$48,076
Companies
17
Transactions
1,450
Medicare Patients
3,410
Medicare Billing
$288,493
Payment Breakdown by Category
Other$1.2M (72.2%)
Travel$342,060 (20.7%)
Consulting$99,328 (6.0%)
Food & Beverage$15,319 (0.9%)
Research$1,992 (0.1%)
Education$418.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 481 | 68.1% |
| Travel and Lodging | $342,060 | 674 | 20.7% |
| Consulting Fee | $99,328 | 36 | 6.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $68,175 | 23 | 4.1% |
| Food and Beverage | $15,319 | 216 | 0.9% |
| Unspecified | $1,992 | 6 | 0.1% |
| Education | $418.46 | 14 | 0.0% |
Payments by Type
General
$1.7M
1,444 transactions
Research
$1,992
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $976,437 | 829 | $0 (2023) |
| Novo Nordisk Inc | $450,524 | 404 | $0 (2024) |
| Dexcom, Inc. | $86,618 | 70 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $85,763 | 72 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $32,864 | 27 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11,116 | 14 | $0 (2024) |
| Lilly USA, LLC | $10,645 | 12 | $0 (2024) |
| BETA BIONICS, INC. | $125.80 | 5 | $0 (2024) |
| Tandem Diabetes Care, Inc. | $86.82 | 4 | $0 (2023) |
| Abbott Laboratories | $70.07 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,076 | 50 | Novo Nordisk Inc ($20,057) |
| 2023 | $111,938 | 114 | Dexcom, Inc. ($53,276) |
| 2022 | $121,543 | 77 | Novo Nordisk Inc ($57,352) |
| 2021 | $111,887 | 79 | Novo Nordisk Inc ($64,638) |
| 2020 | $118,636 | 86 | AstraZeneca Pharmaceuticals LP ($45,832) |
| 2019 | $304,634 | 175 | SANOFI-AVENTIS U.S. LLC ($237,492) |
| 2018 | $354,954 | 362 | SANOFI-AVENTIS U.S. LLC ($250,216) |
| 2017 | $482,774 | 507 | SANOFI-AVENTIS U.S. LLC ($381,081) |
All Payment Transactions
1,450 individual payment records from CMS Open Payments — Page 1 of 58
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: Automated insulin delivery system | ||||||
| 12/16/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: Automated insulin delivery system | ||||||
| 11/26/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| 11/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,298.00 | General |
| Category: Endocrinology | ||||||
| 11/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | In-kind items and services | $1,121.63 | General |
| Category: Endocrinology | ||||||
| 11/20/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: DIABETES | ||||||
| 11/13/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $30.95 | General |
| Category: Endocrinology | ||||||
| 11/08/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| 11/06/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,843.75 | General |
| Category: Diabetes | ||||||
| 10/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: DIABETES | ||||||
| 10/03/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| 09/26/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 09/18/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,447.00 | General |
| Category: Endocrinology | ||||||
| 09/18/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| 09/14/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | In-kind items and services | $1,166.24 | General |
| Category: Endocrinology | ||||||
| 08/07/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 08/07/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Diabetes | ||||||
| 06/27/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 05/30/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| 05/30/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $33.15 | General |
| Category: Automated insulin delivery system | ||||||
| 05/17/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Diabetes | ||||||
| 05/09/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Diabetes | ||||||
| 04/30/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 04/25/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled | SANOFI-AVENTIS U.S. LLC | $1,494 | 3 |
| SENIOR | SANOFI-AVENTIS U.S. LLC | $497.16 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 778 | 1,391 | $229,479 | $84,663 |
| 2022 | 4 | 814 | 1,272 | $221,961 | $77,202 |
| 2021 | 6 | 964 | 1,312 | $245,996 | $81,915 |
| 2020 | 6 | 854 | 959 | $181,388 | $44,713 |
Total Patients
3,410
Total Services
4,934
Medicare Billing
$288,493
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 491 | 930 | $179,739 | $70,254 | 39.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2023 | 246 | 418 | $39,292 | $11,407 | 29.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 16 | 16 | $5,086 | $1,768 | 34.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 25 | 27 | $5,363 | $1,234 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 481 | 804 | $156,183 | $59,340 | 38.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2022 | 225 | 354 | $33,276 | $9,623 | 28.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 53 | 53 | $16,848 | $5,205 | 30.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 55 | 61 | $15,654 | $3,034 | 19.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 449 | 730 | $151,251 | $58,043 | 38.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 122 | 122 | $40,651 | $13,127 | 32.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Facility | 2021 | 161 | 217 | $20,398 | $6,462 | 31.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 81 | 82 | $19,462 | $3,023 | 15.5% |
| 83036 | Hemoglobin a1c level | Facility | 2021 | 140 | 150 | $13,860 | $1,095 | 7.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 11 | 11 | $374.00 | $165.36 | 44.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 299 | 366 | $76,582 | $20,063 | 26.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 127 | 127 | $41,561 | $12,474 | 30.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 178 | 193 | $47,310 | $8,335 | 17.6% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 66 | 69 | $2,346 | $1,436 | 61.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 18 | 18 | $1,206 | $775.62 | 64.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 19 | 19 | $1,273 | $770.40 | 60.5% |
| 82947 | Blood glucose (sugar) level | Facility | 2020 | 135 | 155 | $10,703 | $600.99 | 5.6% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 12 | 12 | $408.00 | $257.88 | 63.2% |
About Dr. Helen Baron, M.D
Dr. Helen Baron, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Rancho Mirage, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295762995.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Helen Baron, M.D has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $48,076 received in 2024. These payments were reported across 1,450 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Baron has provided services to 3,410 Medicare beneficiaries, totaling 4,934 services with total Medicare billing of $288,493. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Rancho Mirage, CA
- Active Since 06/27/2006
- Last Updated 05/20/2021
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1295762995
Products in Payments
- TOUJEO (Drug) $480,975
- SOLIQUA (Drug) $252,179
- Ozempic (Drug) $185,848
- LANTUS (Drug) $99,768
- FARXIGA (Drug) $85,649
- Tresiba (Drug) $72,367
- DEXCOM G7 GSS (161) (Medical Supply) $66,553
- TOUJEO (Biological) $52,606
- Victoza (Drug) $49,761
- RYBELSUS (Drug) $44,606
- Rybelsus (Drug) $43,012
- AMARYL (Drug) $32,713
- Xultophy 100/3.6 (Drug) $25,261
- Kerendia (Drug) $24,671
- SOLIQUA 100/33 (Biological) $22,280
- JARDIANCE (Drug) $21,716
- SOLIQUA 100/33 (Drug) $19,317
- Dexcom G6 Transmitter (Medical Supply) $16,870
- RENVELA (Drug) $13,341
- Non-Covered $6,383
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Rancho Mirage
Dr. Mohamad Alnabelsi, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $4,773
Endocrinology, Diabetes & Metabolism $4,773
Wendy White, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $2,663
Endocrinology, Diabetes & Metabolism $2,663
Elke Jost-Vu, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1,062
Endocrinology, Diabetes & Metabolism $1,062